J&J image loses ground with consumers; Teva, BioSante win FDA nod for testosterone med;

@FiercePharma: Senator wants to attach drug-shortage measure to highway bill: 'Can't wait a year to get this done'--Reuters. Article | Follow @FiercePharma

> Johnson & Johnson ($JNJ) fell in a consumer ranking of corporate image to No. 7, after ranking in the top two for the last dozen years-- since Harris Interactive launched the poll. Report

> Teva Pharmaceutical Industries ($TEVA) and BioSante Pharmaceuticals ($BPAX) won FDA approval for a transdermal testosterone gel for treatment of hypogonadism. Article

> Sanofi ($SNY) inked a deal with Emcure Pharmaceuticals to sell Verorab, a rabies vaccine, in India. News

> Takeda Pharmaceutical said it plans to issue up to $3.2 billion in bonds over two years, to help finance its $12.6 billion acquisition of Nycomed. Story

> Texas is running out of execution drugs and may have to halt lethal injections this summer after drugmakers put restrictions on the necessary anesthetics. News

> Pediatricians are increasingly banning families that choose not to vaccinate their children; some cite worries of contagion in their waiting rooms. Report

Biotech News

@FierceBiotech: BioSante soars on FDA nod for testosterone gel, regains some ground after failure of female libido gel. News | Follow @FierceBiotech

@JohnCFierce: Touting preclin results for a hep C treatment? A desperate cry for attention. BioCryst. Release | Follow @JohnCFierce

@RyanMFierce: UnitedHealth is planning a cloud-based platform, initially for healthcare users, but maybe pharma down the line: Article | Follow @RyanMFierce

@FierceMedDev: Post-Grateful Dead player scores medical hit. Story | Follow @FierceMedDev

> Hep C drug deal frenzy can't be slowed by growing doubts. Article

> Corporate VCs crowd into $43M round for Celladon. News

Medical Device News

> Does Riata recall indicate subpar device surveillance? Story

> Cayenne closes $10M to advance sports med portfolio. Item

> Stryker's Hartman sees salary boosted to $750K, MacMillan negotiates separation agreement. News

> Atossa files for IPO in effort to raise $6M. Report

Drug Delivery News

> Ensysce says carbon nanotubes delivered cancer drug. More

> Titan plans Q3 NDA submission for controlled-release implantable addiction treatment. Article

> Microscopic booms: China, U.S. efforts mull explosive use of nanotech drug delivery. News

> Can Medasys' new drug pump challenge Medtronic? Piece

> FDA biosimilar draft guidance creates drug delivery leeway. Story

Biomarkers News

> Positive results for biomarker based diagnostic CardioSCORE. News

> Collaborators work to create urine test for active TB. Item

> Gates Foundation funds TB biomarker research. Piece

> Progranulin biomarker predicts 5-year outcomes. Article

And Finally... Antibiotics are no help for most sinus infections, despite their common use, a study found. Report

Suggested Articles

Last year at ESMO, AZ and Merck showed Lynparza topped its rivals at fending off prostate cancer. Now, Lynparza has helped patients live longer, too.

Merck and Eisai are trying to take their Keytruda-Lenvima combo into additional cancers, and new data provide a glimpse of where it might go next.

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.